Durability of glycemic control using U-500 insulin.

Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin.

Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.

The use of U-500 insulin in the management of highly insulin resistant diabetic patients is growing. There are a number of reports that have noted the effects of U-500 insulin using multiple daily injections or continuous subcutaneous insulin infusion on hemoglobin A(1c), weight, and total daily insulin dosage. The effect of U-500 insulin use on glycemic control, changes in body weight, total daily insulin dosage, incidence of hypoglycemia, and effect on lipid levels and blood pressure as well as patient satisfaction and quality of life will be reviewed.

Clinical efficacy and patient satisfaction with U-500 insulin use.

Aims: The prevalence of highly insulin-resistant diabetes is increasing and treatment requires the use of very high doses of insulin. This study was performed to analyze efficacy and patient satisfaction with use of U-500 concentrated insulin.

Methods: The medical records of 40 patients using U-500 insulin for at least 3 months were reviewed.

Plasma membrane targeting is essential for Rem-mediated Ca2+ channel inhibition.

The small GTPase Rem is a potent negative regulator of high voltage-activated Ca(2+) channels and a known interacting partner for Ca(2+) channel accessory beta subunits. The mechanism for Rem-mediated channel inhibition remains controversial, although it has been proposed that Ca(V)beta association is required. Previous work has shown that a C-terminal truncation of Rem (Rem-(1-265)) displays reduced in vivo binding to membrane-localized beta 2a and lacks channel regulatory function.